Imperial College London
Portrait Picture

Professor Martin Wilkins

Faculty of Medicine, National Heart & Lung Institute

Professor of Clinical Pharmacology
 
 
 
//

Contact

 

+44 (0)20 3313 6101m.wilkins Website

 
 
//

Assistant

 

Mrs Elizabeth O'Brien +44 (0)20 3313 6101

 
//

Location

 

NIHR Imperial Clinical Research FacilityICTEM buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Ruiter:2015:10.1086/682217,
author = {Ruiter, G and Manders, E and Happé, CM and Schalij, I and Groepenhoff, H and Howard, LS and Wilkins, MR and Bogaard, HJ and Westerhof, N and van, der Laarse WJ and de, Man FS and Vonk-Noordegraaf, A},
doi = {10.1086/682217},
journal = {Pulmonary Circulation},
pages = {466--472},
title = {Intravenous iron therapy in patients with idiopathic pulmonary arterial hypertension and iron deficiency.},
url = {http://dx.doi.org/10.1086/682217},
volume = {5},
year = {2015}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - In patients with idiopathic pulmonary arterial hypertension (iPAH), iron deficiency is common and has been associated with reduced exercise capacity and worse survival. Previous studies have shown beneficial effects of intravenous iron administration. In this study, we investigated the use of intravenous iron therapy in iron-deficient iPAH patients in terms of safety and effects on exercise capacity, and we studied whether altered exercise capacity resulted from changes in right ventricular (RV) function and skeletal muscle oxygen handling. Fifteen patients with iPAH and iron deficiency were included. Patients underwent a 6-minute walk test, cardiopulmonary exercise tests, cardiac magnetic resonance imaging, and a quadriceps muscle biopsy and completed a quality-of-life questionnaire before and 12 weeks after receiving a high dose of intravenous iron. The primary end point, 6-minute walk distance, was not significantly changed after 12 weeks (409 ± 110 m before vs. 428 ± 94 m after; P = 0.07). Secondary end points showed that intravenous iron administration was well tolerated and increased body iron stores in all patients. In addition, exercise endurance time (P < 0.001) and aerobic capacity (P < 0.001) increased significantly after iron therapy. This coincided with improved oxygen handling in quadriceps muscle cells, although cardiac function at rest and maximal [Formula: see text] were unchanged. Furthermore, iron treatment was associated with improved quality of life (P < 0.05). In conclusion, intravenous iron therapy in iron-deficient iPAH patients improves exercise endurance capacity. This could not be explained by improved RV function; however, increased quadriceps muscle oxygen handling may play a role. ( TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT01288651).
AU  - Ruiter,G
AU  - Manders,E
AU  - Happé,CM
AU  - Schalij,I
AU  - Groepenhoff,H
AU  - Howard,LS
AU  - Wilkins,MR
AU  - Bogaard,HJ
AU  - Westerhof,N
AU  - van,der Laarse WJ
AU  - de,Man FS
AU  - Vonk-Noordegraaf,A
DO  - 10.1086/682217
EP  - 472
PY  - 2015///
SN  - 2045-8940
SP  - 466
TI  - Intravenous iron therapy in patients with idiopathic pulmonary arterial hypertension and iron deficiency.
T2  - Pulmonary Circulation
UR  - http://dx.doi.org/10.1086/682217
UR  - http://www.ncbi.nlm.nih.gov/pubmed/26401247
UR  - http://hdl.handle.net/10044/1/31618
VL  - 5
ER  -
Download